Xstrahl to Showcase Radiant™ Aura at Maui Derm Hawaii 2024
Radiant Aura expands office-based radiation therapy treatment options for patients with non-melanoma skin cancers and keloid scarring
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura at the Maui Derm Hawaii 2024 meeting, January 22-26, 2024. Radiant Aura is a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring.
“We are thrilled that Radiant Aura is now commercially available to support the delivery of office-based radiation therapy for patients with NMSC when surgery is not possible, contraindicated, or simply not preferred due to cosmetic concerns,” said Adrian Treverton, CEO of Xstrahl.
Radiant Aura is the only dual modality system that offers both non-invasive electronic brachytherapy (eBt) and superficial radiation therapy (SRT) for NMSC and keloid scarring. The device received U.S. Food and Drug Administration (FDA) 510(k) clearance in July 2023.
Visit Xstrahl at Maui Derm Hawaii 2024, at the Grand Wailea Hotel in Maui, HI from January 22-26, 2024.
# # #
For further information, please contact:
Kelly Withers, National Sales Director
Cell: 602-509-4990 or e-mail: kellywithers@xstrahl.com
About Xstrahl
Xstrahl is a medical technology company that designs radiation delivery devices to support clinical teams and cancer researchers. For more than 25 years, Xstrahl has been shaping the development of superficial and orthovoltage radiation therapy and advancing preclinical radiation research. Xstrahl systems are in operation at more than 700 treatment and research facilities worldwide.
To learn more about Radiant Aura, visit www.radiant-therapy.com
To learn more about all Xstrahl clinical and research systems, visit www.xstrahl.com